Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity

Key Points Question Can plasma biomarker analytes be used in a low-resource community to improve clinical accuracy in diagnosing Alzheimer disease (AD)? Findings In this decision analytical modeling study of 746 Caribbean Hispanic individuals from the Dominican Republic and New York, a panel of plasma biomarkers, including phosphorylated tau181 (P-tau181) and the ratio of P-tau181 to amyloid-β Aβ42, identified biological evidence of AD. A proportion of asymptomatic individuals without dementia had biomarker evidence of AD and may be presymptomatic, while a proportion of affected individuals with dementia lacked biomarker evidence of AD and may have other dementia disorders. Meaning These findings suggest that plasma biomarkers can improve the specificity of the clinical diagnosis of AD and can detect biological evidence of the disease in asymptomatic individuals in a low-resource environment where other types of diagnostic procedures are limited.

[1]  Nick C Fox,et al.  Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  C. Jack,et al.  Performance of plasma phosphorylated tau 181 and 217 in the community , 2022, Nature Medicine.

[3]  M. Gorno-Tempini,et al.  Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration , 2022, Neurology.

[4]  C. Jack,et al.  Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology , 2022, Alzheimer's & dementia.

[5]  C. Jack,et al.  Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes , 2021, Alzheimer's research & therapy.

[6]  Sterling C. Johnson,et al.  Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status , 2021, Translational Psychiatry.

[7]  K. Blennow,et al.  Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[8]  K. Blennow,et al.  Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study , 2021, The Lancet Neurology.

[9]  C. Jack,et al.  Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. , 2021, JAMA neurology.

[10]  K. Blennow,et al.  Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease , 2021, Brain : a journal of neurology.

[11]  K. Blennow,et al.  Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  C. Schimming,et al.  Effect of Social Determinants of Health on Cognition and Risk of Alzheimer Disease and Related Dementias. , 2021, Clinical therapeutics.

[13]  M. Mielke,et al.  Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial , 2021, Journal of Alzheimer's disease reports.

[14]  R. Bateman,et al.  Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau , 2021, EMBO molecular medicine.

[15]  K. Blennow,et al.  Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease , 2021, JAMA neurology.

[16]  K. Blennow,et al.  Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease , 2020, Annals of clinical and translational neurology.

[17]  D. Walsh,et al.  Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease , 2020, Brain : a journal of neurology.

[18]  Patrick J. Lao,et al.  Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study , 2020, medRxiv.

[19]  P. Scheltens,et al.  Amyloid‐β PET and CSF in an autopsy‐confirmed cohort , 2020, medRxiv.

[20]  D. Airey,et al.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease , 2020, Nature Communications.

[21]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[22]  James Jaworski,et al.  Whole genome sequencing of Caribbean Hispanic families with late‐onset Alzheimer's disease , 2018, Annals of clinical and translational neurology.

[23]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[24]  K. Blennow,et al.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease , 2016, Annals of clinical and translational neurology.

[25]  Sana Siddiqui,et al.  Classification of Alzheimer Diagnosis from ADNI Plasma Biomarker Data , 2013, BCB.

[26]  C. Jack,et al.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI , 2011, Acta Neuropathologica.

[27]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[28]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[29]  Magda Tsolaki,et al.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases , 2015, Nature Reviews Neurology.